Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tarsus Pharmaceuticals (TARS) Accumulated Expenses (2020 - 2025)

Tarsus Pharmaceuticals (TARS) has 5 years of Accumulated Expenses data on record, last reported at $15.8 million in Q4 2024.

  • For Q4 2024, Accumulated Expenses rose 19.46% year-over-year to $15.8 million; the TTM value through Dec 2024 reached $15.8 million, up 19.46%, while the annual FY2024 figure was $15.8 million, 19.46% up from the prior year.
  • Accumulated Expenses reached $15.8 million in Q4 2024 per TARS's latest filing, up from $8.0 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $15.8 million in Q4 2024 and bottomed at $520000.0 in Q3 2020.
  • Average Accumulated Expenses over 5 years is $5.1 million, with a median of $4.1 million recorded in 2022.
  • Peak YoY movement for Accumulated Expenses: skyrocketed 331.92% in 2021, then rose 19.46% in 2024.
  • A 5-year view of Accumulated Expenses shows it stood at $1.0 million in 2020, then soared by 169.04% to $2.8 million in 2021, then skyrocketed by 97.25% to $5.5 million in 2022, then surged by 139.99% to $13.2 million in 2023, then rose by 19.46% to $15.8 million in 2024.
  • Per Business Quant database, its latest 3 readings for Accumulated Expenses were $15.8 million in Q4 2024, $8.0 million in Q2 2024, and $6.0 million in Q1 2024.